RECRUITING

Contoura With Phorcides Compared to Wavefront Optimized LASIK

Conditions

Myopia Astigmatism Visual acuity Refractive outcome LASIK Contrast sensitivity Wavefront Optimized Topography-guided

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

Comparing post-operative visual acuity and patient reported satisfaction between Contoura with Phorcides and WaveLight Wavefront Optimized.

Official Title

Comparison of Visual Acuity and Quality of Life Following Contoura With Phorcides Compared to WaveLight Wavefront Optimized LASIK

Quick Facts

Study Start:2022-08-15

Study Completion:2023-12-01

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:RECRUITING

Study ID

NCT05486546

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:21 Years to 38 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:No

Standard Ages:ADULT

Inclusion Criteria	Exclusion Criteria
* Patients at least age 21 years of age undergoing LASIK eye surgery * Willing and able to comprehend informed consent and complete 1 month post-op visit * Potential postoperative BCDVA of 20/20 or better in each eye based on Investigator's medical opinion * Candidates for Contoura with Phorcides (Myopic, astigmatism \<3.0D) * Both eyes targeted for plano * Pre-operative total corneal Pachymetry 490um or above * Stable refractive error \<0.50D change in preceding year * Good general and ocular health * Pre-operative exam completed within three months of surgery * SCL discontinued 3 days prior to pre-op exam and the procedure * Pachymetry above 490 with residual greater than 270um * Candidates who, as determined by the investigator, can safely undergo LASIK	* Patients under 21 years of age * Concomitant ocular condition which would limit the BCVA at the discretion of the surgeon * Patients with usual relative and absolute contraindications for LASIK surgery (Patients with severe dry eye, recurrent corneal erosion, uncontrolled Glaucoma, collagen vascular disorders, keratoconus or signs of keratoconus, uncontrolled Diabetes, Herpes) * Pachymetry below 490 * Autoimmune or immunodeficiency diseases * Pregnant or nursing women * Patients with signs of inability to understand consent for study and procedure planned * Patients with history of previous ocular surgery * Patients with strabismus or amblyopia * Patients that have a BCDVA of 20/25 or worse in either eye

Inclusion Criteria

Exclusion Criteria

* Patients at least age 21 years of age undergoing LASIK eye surgery
* Willing and able to comprehend informed consent and complete 1 month post-op visit
* Potential postoperative BCDVA of 20/20 or better in each eye based on Investigator's medical opinion
* Candidates for Contoura with Phorcides (Myopic, astigmatism \<3.0D)
* Both eyes targeted for plano
* Pre-operative total corneal Pachymetry 490um or above
* Stable refractive error \<0.50D change in preceding year
* Good general and ocular health
* Pre-operative exam completed within three months of surgery
* SCL discontinued 3 days prior to pre-op exam and the procedure
* Pachymetry above 490 with residual greater than 270um
* Candidates who, as determined by the investigator, can safely undergo LASIK

* Patients under 21 years of age
* Concomitant ocular condition which would limit the BCVA at the discretion of the surgeon
* Patients with usual relative and absolute contraindications for LASIK surgery (Patients with severe dry eye, recurrent corneal erosion, uncontrolled Glaucoma, collagen vascular disorders, keratoconus or signs of keratoconus, uncontrolled Diabetes, Herpes)
* Pachymetry below 490
* Autoimmune or immunodeficiency diseases
* Pregnant or nursing women
* Patients with signs of inability to understand consent for study and procedure planned
* Patients with history of previous ocular surgery
* Patients with strabismus or amblyopia
* Patients that have a BCDVA of 20/25 or worse in either eye

Contacts and Locations

Study Contact

Daniel Terveen, MD

CONTACT

605-645-7999

daniel.terveen@vancethompsonvision.com

Elise Meide, M.S.

CONTACT

605-645-0444

elise.reid@coyotes.usd.edu

Study Locations (Sites)

Vance Thompson Vison

Bozeman, Montana, 57105

United States

Vance Thompson Vision

Omaha, Nebraska, 57105

United States

Vance Thompson Vision

Fargo, North Dakota, 57105

United States

Vance Thompson Vision

Sioux Falls, South Dakota, 57108

United States

Collaborators and Investigators

Sponsor: Daniel Terveen

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2022-08-15

Study Completion Date2023-12-01

Study Record Updates

Study Start Date2022-08-15

Study Completion Date2023-12-01

Terms related to this study

Keywords Provided by Researchers

Visual acuity
Refractive outcome
LASIK
Contrast sensitivity
Wavefront Optimized
Topography-guided

Additional Relevant MeSH Terms

Myopia
Astigmatism